RESUMEN
PURPOSE OF REVIEW: To bring together and annotate publications about personalised external aortic root support reported in the 18âmonths preceding submission. RECENT FINDINGS: The total number of personalised external aortic root support (PEARS) operations is now approaching 700 in 30 centres in Australia, Belgium, Brazil, Czech Republic, Great Britain, Greece, Ireland, Malaysia, Netherlands, New Zealand, Poland and Slovakia. There are continued reports of stability of aortic dimensions and aortic valve function with the only exceptions known being where the surgeon has deviated from the instructions for use of the device. The median root diameter of Marfan patients having PEARS was 47âmm suggesting that the existing criterion of 50âmm is due for reconsideration. The peri-operative mortality currently estimated to be less than 0.3%. The first recipient remains alive and well after 18âyears. The use of PEARS as an adjunct to the Ross operation to support the pulmonary autograft is being explored in several centres. SUMMARY: The operation requires proctoring and adherence to a strict operative protocol and with those precautions excellent results are attained. The evidence and opinions provided in the cited publications indicate that PEARS is a proven and successful prophylactic operation for aortic root aneurysm.
Asunto(s)
Aneurisma de la Aorta Torácica , Insuficiencia de la Válvula Aórtica , Síndrome de Marfan , Válvula Pulmonar , Aneurisma de la Aorta Torácica/cirugía , Válvula Aórtica/cirugía , Autoinjertos , Prótesis Vascular , Humanos , Síndrome de Marfan/cirugía , Trasplante AutólogoRESUMEN
Pulmonary metastasectomy for sarcoma is surgery without proven benefit, and in the light of a randomized controlled trial examining pulmonary metastasectomy in colorectal cancer, it should be questioned.
Asunto(s)
Neoplasias Colorrectales , Neoplasias Pulmonares , Metastasectomía , Sarcoma , Neoplasias de los Tejidos Blandos , Neoplasias Colorrectales/cirugía , Humanos , Neoplasias Pulmonares/cirugía , Neumonectomía , Sarcoma/cirugíaRESUMEN
AIM: The aim was to assess the health utility of lung metastasectomy in the treatment of patients with colorectal cancer (CRC) using the EQ-5D-3L questionnaire. METHODS: Multidisciplinary CRC teams at 14 sites recruited patients to a two-arm randomized controlled trial-Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC). Remote randomization was used, stratified by site and with minimization for seven known confounders. Participants completed the EQ-5D-3L questionnaire together with other patient reported outcome measures at randomization and then again at 3, 6, 12 and 24 months. These were returned by post to the coordinating centre. RESULTS: Between December 2010 and December 2016, 93 participants were randomized, 91 of whom returned questionnaires. Survival and patient reported quality of life have been published previously, revealing no significant differences between the trial arms. Described here are patient reported data from the five dimensions of the EQ-5D-3L and the visual analogue scale (VAS) health state. No significant difference was seen at any time point. The estimated difference between control and metastasectomy patients was -0.23 (95% CI -0.113, 0.066) for the composite 0 to 1 index scale based on the descriptive system and 0.123 (95% CI -7.24, 7.49) for the 0 to 100 VAS scale. CONCLUSIONS: Following lung metastasectomy for CRC, no benefit was demonstrated for health utility, which alongside a lack of a survival or quality of life benefit calls into question the widespread use of the procedure.
Asunto(s)
Neoplasias Colorrectales , Metastasectomía , Neoplasias Colorrectales/cirugía , Humanos , Pulmón , Calidad de Vida , Encuestas y CuestionariosRESUMEN
AIM: Evidence on patterns of use of pulmonary metastasectomy in colorectal cancer patients is limited. This population-based study aims to investigate the use of pulmonary metastasectomy in the colorectal cancer population across the English National Health Service (NHS) and quantify the extent of any variations in practice and outcome. METHODS: All adults who underwent a major resection for colorectal cancer in an NHS hospital between 2005 and 2013 were identified in the COloRECTal cancer data Repository (CORECT-R). All inpatient episodes corresponding to pulmonary metastasectomy, occurring within 3 years of the initial colorectal resection, were identified. Multi-level logistic regression was used to determine patient and organizational factors associated with the use of pulmonary metastasectomy for colorectal cancer, and Kaplan-Meier and Cox models were used to assess survival following pulmonary metastasectomy. RESULTS: In all, 173 354 individuals had a major colorectal resection over the study period, with 3434 (2.0%) undergoing pulmonary resection within 3 years. The frequency of pulmonary metastasectomy increased from 1.2% of patients undergoing major colorectal resection in 2005 to 2.3% in 2013. Significant variation was observed across hospital providers in the risk-adjusted rates of pulmonary metastasectomy (0.0%-6.8% of patients). Overall 5-year survival following pulmonary resection was 50.8%, with 30-day and 90-day mortality of 0.6% and 1.2% respectively. CONCLUSIONS: This study shows significant variation in the rates of pulmonary metastasectomy for colorectal cancer across the English NHS.
Asunto(s)
Neoplasias Colorrectales , Neoplasias Pulmonares , Metastasectomía , Adulto , Neoplasias Colorrectales/cirugía , Humanos , Neoplasias Pulmonares/cirugía , Pronóstico , Modelos de Riesgos Proporcionales , Estudios Retrospectivos , Medicina Estatal , Tasa de SupervivenciaRESUMEN
AIM: The aim of this work was to examine the burden of further treatments in patients with colorectal cancer following a decision about lung metastasectomy. METHOD: Five teams participating in the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) study provided details on subsequent local treatments for lung metastases, including the use of chemotherapy. For patients in three groups (no metastasectomy, one metastasectomy or multiple local interventions), baseline factors and selection criteria for additional treatments were examined. RESULTS: The five teams recruited 220 patients between October 2010 and January 2017. No lung metastasectomy was performed in 51 patients, 114 patients had one metastasectomy and 55 patients had multiple local interventions. Selection for initial metastasectomy was associated with nonelevated carcinoembryonic antigen, fewer metastases and no prior liver metastasectomy. These patients also had better Eastern Cooperative Oncology Group scores and lung function at baseline. Four sites provided information on chemotherapy in 139 patients: 79 (57%) had one to five courses of chemotherapy, to a total of 179 courses. The patterns of survival after one or multiple metastasectomy interventions showed evidence of guarantee-time bias contributing to an impression of benefit over no metastasectomy. After repeated metastasectomy, a significantly higher risk of death was observed, with no apparent reduction in chemotherapy usage. CONCLUSION: Repeated metastasectomy is associated with a higher risk of death without reducing the use of chemotherapy. Continued monitoring without surgery might reassure patients with indolent disease or allow response assessment during systemic treatment. Overall, the carefully collected information from the PulMICC study provides no indication of an important survival benefit from metastasectomy.
Asunto(s)
Neoplasias Colorrectales , Neoplasias Pulmonares , Metastasectomía , Estudios de Cohortes , Neoplasias Colorrectales/terapia , Humanos , Neoplasias Pulmonares/terapia , Pronóstico , Tasa de SupervivenciaRESUMEN
AIM: We wanted to examine survival in patients with resected colorectal cancer (CRC) whose lung metastases are or are not resected. METHODS: Teams participating in the study of Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) identified potential candidates for lung metastasectomy and invited their consent to join Stage 1. Baseline data related to CRC and fitness for surgery were collected. Eligible patients were invited to consent for randomization in the PulMiCC randomized controlled trial (Stage 2). Sites were provided with case report forms for non-randomized patients to record adverse events and death at any time. They were all reviewed at 1 year. Baseline and survival data were analysed for the full cohort. RESULTS: Twenty-five clinical sites recruited 512 patients from October 2010 to January 2017. Data collection closed in October 2020. Before analysis, 28 patients with non-CRC lung lesions were excluded and three had withdrawn consent leaving 481. The date of death was known for 292 patients, 136 were alive in 2020 and 53 at earlier time points. Baseline factors and 5-year survival were analysed in three strata: 128 non-randomized patients did not have metastasectomy; 263 had elective metastasectomy; 90 were from the randomized trial. The proportions of solitary metastases for electively operated and non-operated patients were 69% and 35%. Their respective 5-year survivals were 47% and 22%. CONCLUSION: Survival without metastasectomy was greater than widely presumed. Difference in survival appeared to be largely related to selection. No inference can be drawn about the effect of metastasectomy on survival in this observational study.
Asunto(s)
Neoplasias Colorrectales , Neoplasias Pulmonares , Metastasectomía , Estudios de Cohortes , Humanos , Neoplasias Pulmonares/cirugía , Factores de RiesgoAsunto(s)
Neoplasias Colorrectales , Neoplasias Pulmonares , Metastasectomía , Ensayos Clínicos Controlados Aleatorios como Asunto , Humanos , Neoplasias Colorrectales/patología , Neoplasias Colorrectales/cirugía , Neoplasias Pulmonares/cirugía , Neoplasias Pulmonares/secundario , Neoplasias Pulmonares/patología , NeumonectomíaAsunto(s)
Neoplasias Colorrectales , Neoplasias Pulmonares , Metastasectomía , Ablación por Radiofrecuencia , Neoplasias Colorrectales/diagnóstico por imagen , Neoplasias Colorrectales/cirugía , Humanos , Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Pulmonares/cirugía , Estudios Prospectivos , Tasa de SupervivenciaRESUMEN
3rd Mediterranean Symposium on Thoracic Surgical Oncology, Catania, Italy, 21-22 April 2016 Surgeons presented their experience on videothoracoscopic lobectomy at the 3rd Mediterranean Symposium on Thoracic Surgical Oncology. The audience did not question that lobectomy could be done safely and as completely by videothoracoscopic techniques provided it was in expert and practiced hands and suitable patients. The question addressed here is whether video-assisted thoracic surgery can replace thoracotomy as a standard of care in patients suitable for either approach. To determine which provides the better outcome in terms of long-term survival with equivalent quality of life, would require direct comparison in pragmatic randomized controlled trials.
Asunto(s)
Neoplasias Pulmonares/cirugía , Neumonectomía/métodos , Ensayos Clínicos Controlados Aleatorios como Asunto , Cirugía Torácica Asistida por Video/métodos , Humanos , Laparoscopía/métodos , Neoplasias Pulmonares/mortalidad , Neoplasias Pulmonares/patología , Neumonectomía/normas , Cirugía Torácica Asistida por Video/normas , Resultado del TratamientoRESUMEN
Third Mediterranean Symposium on Thoracic Surgical Oncology, Catania, Italy, 21-22 April 2016 The primary justification for mediastinal lymphadenectomy is that it provides more complete nodal staging to help select best adjuvant treatments. There is a secondary argument that dissection of nodes might remove otherwise unrecognized nodal disease to increase the chance of cure. They have to be thought through again as patients look for less invasive treatments for their cancers such as videothoracoscopy and stereotactic radiotherapy. Evidence from analysis of Surveillance, Epidemiology and End Results data indicated that sampling or dissection can be performed adequately by surgeons using videothoracoscopy but stereotactic radiotherapy of its nature precludes intraoperative lymph node dissection and yet is being promoted as equivalent treatment. Consideration of these issues requires re-examination of the evidence that lymphadenectomy influences survival.